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This commentary refers to ‘Clinical impact of thrombect-
omy in acute ST-elevation myocardial infarction: an indi-
vidual patient-data pooled analysis of 11 trials’†, by
F. Burzotta et al., on page 2193
Primary percutaneous coronary intervention (PCI), a life-saving act,
has been recommended as a Class I–Level of Evidence A indi-
cation by the 2008 Society Guidelines on the management of myo-
cardial infarction in patients with persistent ST-segment elevation
(STEMI).1 The recently launched ‘Stent For Life’ initiative, endorsed
by the Society, EAPCI, the working group on Acute Cardiac Care,
national societies and EUCOMED, aims to implement primary PCI
in .70% of all STEMI patients and to achieve primary PCI rates
.600/million/year in Europe.2 Therefore, one can assume that
primary PCI will take an important place in the overall practice
of the European interventional cardiologist. Consequently, achiev-
ing optimal myocardial perfusion will be the cardiologists’ daily
concern.
In the era of fibrinolysis, the TIMI (thrombolysis in myocardial
infarction) flow was considered the gold standard for the assess-
ment of reperfusion during STEMI. With the advent of primary
PCI, it became quickly apparent that the TIMI flow was no longer
the reference for the judgement of reperfusion at tissue level. In
up to 40% of patients undergoing primary PCI, a persistant
ST-elevation can be observed despite the presence of a TIMI 3
flow.3 The mechanism, of this so-called ‘no-reflow’ phenomenon
is complex and multifactorial. It involves distal embolization of the
thrombus during mechanical instrumentation of the infarct-related
artery but also reperfusion injury.4 Prevention of no-reflow is a
major objective during primary PCI as this condition has repeatly
been associated with a worse prognosis on follow-up.4 In this
respect, the current STEMI guideline recommend a pharmacological
(abciximab) and mechanical (manual thrombus aspiration) strategy
with a Class IIA–Level of Evidence B indication.1 Mechanical aspira-
tion had been added at the last moment to the 2008 STEMI guide-
lines after the publication of the 1-year follow-up of the randomized
TAPAS trial, which demonstrated a lower mortality at 1 year with
aspiration compared with control.5
Burzotta et al. have presented a meta-analysis with 10 additional
randomized controlled trials on thrombectomy during primary PCI
(ATTEMPT).6 They identified 17 trials between 2003 and 2008 on
a MEDLINE search expanded to the websites of the major cardiol-
ogy scientific societies and the TCT and EuroPCR congresses.
Eleven investigators agreed to provide a total of 2686 individual
patient data for a pooled analysis. The primary endpoint was all-
cause mortality and a subgroup analysis was pre-defined on the
type of thrombectomy technique and the administration of IIb/
IIIa antagonists. The investigators were requested to provide the
longest follow-up available.
The main findings of the ATTEMPT study may have important
practical implications. First, this meta-analysis confirms the key
message from the large, single-centre TAPAS study: systematic
thrombectomy during primary PCI improves 1-year survival.
Secondly, survival benefit is confined to manual thrombectomy
only. Finally, additional survival benefit is observed in patients
treated with IIb/IIIa antagonists. Basically, there are three simple
messages for best practice of primary PCI: routine thrombectomy,
manual aspiration, and systematic administration of IIb/IIIa
antagonists.
The conclusions of the authors are reinforced by the positive
elements of the meta-analysis. This is a pooled analysis of individual
patient data, investigator driven, without any financial support. Fur-
thermore, adequate statistics were applied to check the internal
validity and quality of the contributing studies as well as publication
bias. Finally, the follow-up of each study was updated and pro-
longed from a median of 135 to 365 days for the present
meta-analysis. This extended follow-up is one of the strongest
components of the ATTEMPT study as new clinical data confirm
a long-lasting survival benefit from manual thrombectomy.
In general, a meta-analysis is subject to individual differences in
definitions and endpoints and is dependent on the quality of
each contribution. Again, the authors tried to circumvent these
concerns by citing ‘validated statistical analyses’. These do not
abrogate the arguments. In particular, interpretation of the second-
ary endpoints (such as myocardial infarction and the need for rein-
tervention) is more subject to error. Their role in the ATTEMPT
The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.
* Corresponding author. Tel: þ41 21 314 00 10, Fax: þ41 21 314 00 67, Email: eric.eeckhout@chuv.ch
† doi:10.1093/eurheartj/ehp348
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.
European Heart Journal (2009) 30, 2180–2181
doi:10.1093/eurheartj/ehp349
study is unclear in view of the hard and positive mortality endpoint.
Finally, only the death rate matters.
Besides the type of thrombectomy and the use of IIb/IIIa
antagonists, several other subgroups were defined. They included
the presence of diabetes, time to reperfusion, the infarct-related
artery, and the baseline TIMI flow. Unfortunately, none of these
subgroups was adequately powered and no relevant conclusions
could be drawn. At present, ATTEMPT confirms that default
thrombectomy improves survival. Even if, from a pragmatic point
of view, thrombectomy may be questionnable in the case of
TIMI 3 flow with a low thrombus burden, ATTEMPT does not
answer this practical question. This issue would require a dedicated
trial.
The major limitation of ATTEMPT undoubtly is the absence of
six out of 17 eligible trials (accounting for 1019 patients) due to
investigators’ refusal. As a consequence, 88% of studies on
manual vs. only 44% for non-manual thrombectomy were included.
This additionally imbalances the non-direct comparison in favour of
manual thrombectomy, even if a careful literature review of each
individual absent trial reveals negative results.
Still, one may wonder why non-manual thrombectomy performs
worse. Even if non-manual catheters may theoretically extract
more thrombus, they are more difficult to operate and certainly
require a longer learning curve than simple manual aspiration. In
this perspective, the first randomized trial investigating the efficacy
of a non-manual thrombectomy device in saphenous vein grafts
(SAFER) demonstrated that, even if successful application of the
device resulted in a lower complication rate at 30 days (7.9% vs.
16.5%), technical failure resulted in a higher complication rate
than control (25%). It must be reminded that saphenous vein
graft interventions and primary PCI have a common denominator
(the risk for plaque–thrombus embolisation) and a common tool
for its prevention (distal protection and/or non-manual thrombect-
omy, basically being the same devices). Therefore, the technical
challenge of non-manual thrombectomy may well be the main
reason for the negative results in the present meta-analysis.
This brings us to the title of this editorial that applies to many
fields in interventional cardiology. In general, interventional tech-
nology should be kept simple to allow a generalized and optimal
application. At present, manual thrombectomy should be con-
sidered standard practice during primary PCI.
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